Aurobindo's US Respiratory Filing Could Rival Teva's Qvar
As Indian Company Enters Fray For COVID-19 Vaccine
Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.
